[Cambridge, USA / Split, Croatia] December 8th, 2021.
Agilathon and Medable announced a multi-year strategic partnership to deliver decentralized clinical trials globally.
Medable, the leader in decentralized clinical trials (DCT), has chosen Agilathon, a world-class expert in trial delivery, as their strategic partner to support a global pipeline of studies. Agilathon will help scale Medable through development, data collection, and trial delivery, aiming to meet ambitious targets.
“We chose to work with Agilathon because they have 15+ years of industry experience developing, scaling, and validating electronic Patient Reported Outcomes (ePROs),” said Andrea Valente, COO at Medable. “They are committed to our vision of transforming the industry through a patient-centered, high-quality user experience. Agilathon is part of our competitive advantage.”
“While we have delivered over 1,000 studies over the past decade, it was clear to us that Medable had a bold, grand vision that will transform the industry, and that is something we are eager to be part of,” said Furqan Nazeeri, Partner at Agilathon. “We know digital transformation and our team is motivated to help develop drugs that will beat cancer, diabetes, migraines, dementia and more. Medable couldn’t be more aligned with our values, and we look forward to growing together.”
In addition to providing support to scale their DCT practice, Agilathon will be supporting Medable’s strategic product initiatives across the organization.
Agilathon is a professional services firm focusing on decentralized mobile clinical trial innovation. The company has more than 15 years of experience working with industry-leading partners to develop electronic Clinical Outcome Assessment (eCOA) and decentralized clinical trial solutions across over 1,000 diverse phase three studies in multiple therapeutic areas including diabetes, migraines, cancer, dementia and more.
Agilathon aims to be the most sought-after technology enablement company in the clinical trial space, with plans to double in size over the next year by growing its mission-oriented team.
Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention, and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data, and interfaces to accelerate trial execution. Medable connects patients, sites, and clinical trial teams to improve patient access, experience, and outcomes. Medable is valued at $2.1 billion and has raised $500 million, including $304 million in new venture capital this quarter alone.
For more information, contact: email@example.com